Berenberg Bank Has Lowered Expectations for Haleon (LON:HLN) Stock Price

Haleon (LON:HLN) had its price target lowered by equities research analysts at Berenberg Bank from GBX 514 to GBX 365 in a report issued on Monday, Digital Look reports. The firm currently has a “buy” rating on the stock. Berenberg Bank‘s price objective would indicate a potential upside of 14.87% from the stock’s current price.

HLN has been the subject of several other research reports. Jefferies Financial Group restated a “buy” rating and issued a GBX 400 target price on shares of Haleon in a report on Friday. Deutsche Bank Aktiengesellschaft raised shares of Haleon to a “hold” rating and reduced their price target for the company from GBX 320 to GBX 310 in a research report on Friday. Finally, Royal Bank Of Canada upped their price objective on shares of Haleon from GBX 370 to GBX 390 and gave the company a “sector perform” rating in a research note on Tuesday, August 11th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of GBX 356.

Haleon Trading Down 0.5%

LON:HLN opened at GBX 317.75 on Monday. Haleon has a 12-month low of GBX 310.50 and a 12-month high of GBX 433.60. The firm has a market cap of £27.95 billion, a PE ratio of 17.56, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24. The company has a current ratio of 0.69, a quick ratio of 0.93 and a debt-to-equity ratio of 50.38. The stock has a fifty day moving average price of GBX 352.97 and a 200 day moving average price of GBX 360.40.

Haleon (LON:HLN) last posted its earnings results on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a return on equity of 9.89% and a net margin of 14.55%. Sell-side analysts anticipate that Haleon will post 19.50 earnings per share for the current fiscal year.

Haleon declared that its Board of Directors has initiated a share repurchase program on Thursday, October 29th that allows the company to buy back £500 million in shares. This buyback authorization allows the company to buy up to 1.8% of its shares through open market purchases. Stock buyback programs are often an indication that the company’s management believes its stock is undervalued.

Haleon News Roundup

Here are the key news stories impacting Haleon this week:

• Positive Sentiment: Haleon approved a £500 million share repurchase program, equivalent to as much as 1.8% of outstanding shares. The buyback could support earnings per share and signals that management views the shares as undervalued. Haleon Q3 Revenue Rises; Trims Annual Revenue Growth Outlook; Launches £500 Mln Share Buyback
• Positive Sentiment: Jefferies reaffirmed its buy rating and set a GBX 400 price target, implying substantial upside from recent trading levels and providing some support for the stock. Jefferies reaffirms Haleon buy rating
• Neutral Sentiment: Deutsche Bank upgraded Haleon to hold but reduced its price target to GBX 310 from GBX 320. The change reflects a more balanced view rather than a strongly bullish signal. Deutsche Bank Haleon rating update
• Neutral Sentiment: Institutional positioning was mixed, with some major investors adding Haleon shares while others reduced holdings. These moves may influence sentiment but do not establish a clear near-term direction.
• Negative Sentiment: Haleon reported third-quarter organic revenue growth of 2.6%, below expectations, and cut its 2026 organic revenue growth outlook to about 2.5% from a previous 3%–5% range. Weak cough, cold and flu demand in North America, disruption to Centrum products in China, and a planned Brazil go-to-market change contributed to the downgrade. Haleon drops after Q3 sales miss and lower 2026 growth outlook

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.